Expression analysis of 11 TAAs in tumor samples confirmed that HNRPL, WHSC2, SART3, CypB, PTHrP, and UBE2V were expressed in most tumor cells, validating their immunogenicity, while pre-existing IgG responses in patient plasma further supported their potential for immune enhancement. This evidence concerns the gene NELFA and neoplasm.